Asfar S Azmi

InstitutionWayne State University School of Medicine
AddressDetroit
Michigan
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 1 Covid-19 publications, with a maximum of 1 publications in June 2020
    All Publications
    Bar chart showing 106 publications over 15 distinct years, with a maximum of 15 publications in 2011
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Uddin MH, Zonder JA, Azmi AS. Exportin 1 inhibition as antiviral therapy. Drug Discov Today. 2020 10; 25(10):1775-1781. PMID: 32569833.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    2. Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R. Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. Heliyon. 2019 Aug; 5(8):e02290. PMID: 31508518.
      Citations:    
    3. Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2019 Aug 02; 11(8). PMID: 31382411.
      Citations: 4     
    4. Sexton RE, Mpilla G, Kim S, Philip PA, Azmi AS. Ras and exosome signaling. Semin Cancer Biol. 2019 02; 54:131-137. PMID: 30769101.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    5. Aboukameel A, Muqbil I, Baloglu E, Senapedis W, Landesman Y, Argueta C, Kauffman M, Chang H, Kashyap T, Shacham S, Neggers JE, Daelemans D, Heath EI, Azmi AS. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget. 2018 Oct 19; 9(82):35327-35342. PMID: 30450161.
      Citations: 5     Fields:    
    6. Azmi AS. Nuclear export mechanisms of circular RNAs: size does matter. Noncoding RNA Investig. 2018 Sep; 2. PMID: 30393780.
      Citations: 2     
    7. Azmi AS. Some chinks in RAS armor. Semin Cancer Biol. 2019 02; 54:iii-iv. PMID: 30092255.
      Citations:    Fields:    Translation:HumansCells
    8. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Cancer Lett. 2018 06 01; 423:153. PMID: 29606293.
      Citations:    Fields:    
    9. Muqbil I, Azmi AS, Mohammad RM. Nuclear Export Inhibition for Pancreatic Cancer Therapy. Cancers (Basel). 2018 May 07; 10(5). PMID: 29735942.
      Citations: 6     
    10. Gawde KA, Sau S, Tatiparti K, Kashaw SK, Mehrmohammadi M, Azmi AS, Iyer AK. Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids Surf B Biointerfaces. 2018 Jul 01; 167:8-19. PMID: 29625422.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    11. Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS. Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opin Ther Targets. 2018 01; 22(1):9-17. PMID: 29207896.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    12. Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 2017 Oct 10; 8(47):82144-82155. PMID: 29137251.
      Citations: 19     Fields:    
    13. Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget. 2017 Jul 04; 8(27):44295-44311. PMID: 28574828.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    14. Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-?B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016 Nov 29; 7(48):78883-78895. PMID: 27713151.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    15. Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 01; 16(1):76-87. PMID: 28062705.
      Citations: 28     Translation:HumansAnimalsCells
    16. Azmi AS, Mohammad RM. Targeting Cancer at the Nuclear Pore. J Clin Oncol. 2016 12; 34(34):4180-4182. PMID: 27863200.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    17. Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Lett. 2016 12 28; 383(2):309-317. PMID: 27693556.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    18. Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med. 2016 Jun 16; 5(6). PMID: 27322337.
      Citations: 12     
    19. Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016 Feb; 36:95-104. PMID: 26804424.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    20. Azmi AS. Opening a Pandora's (F)-box in cancer. Semin Cancer Biol. 2016 Feb; 36:1-2. PMID: 26706999.
      Citations:    Fields:    Translation:HumansAnimalsCells
    21. Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Sci Rep. 2015 Nov 05; 5:16077. PMID: 26536918.
      Citations: 13     Fields:    Translation:HumansCells
    22. Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis C, Boosani CS, Poudyal D, Stafforini DM, Bhakta D, Niccolai E, Guha G, Vasantha Rupasinghe HP, Fujii H, Honoki K, Mehta K, Aquilano K, Lowe L, Hofseth LJ, Ricciardiello L, Ciriolo MR, Singh N, Whelan RL, Chaturvedi R, Ashraf SS, Shantha Kumara HMC, Nowsheen S, Mohammed SI, Keith WN, Helferich WG, Yang X. A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol. 2015 Dec; 35 Suppl:S151-S184. PMID: 25951989.
      Citations: 30     Fields:    Translation:HumansCells
    23. Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015 Dec; 35 Suppl:S78-S103. PMID: 25936818.
      Citations: 146     Fields:    Translation:HumansCells
    24. Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec; 35 Suppl:S25-S54. PMID: 25892662.
      Citations: 136     Fields:    Translation:HumansCells
    25. Yaswen P, MacKenzie KL, Keith WN, Hentosh P, Rodier F, Zhu J, Firestone GL, Matheu A, Carnero A, Bilsland A, Sundin T, Honoki K, Fujii H, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Niccolai E, Aquilano K, Ashraf SS, Nowsheen S, Yang X. Therapeutic targeting of replicative immortality. Semin Cancer Biol. 2015 Dec; 35 Suppl:S104-S128. PMID: 25869441.
      Citations: 18     Fields:    Translation:HumansCells
    26. Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, Helferich WG, Heneberg P, Honoki K, Keith WN, Kerkar SP, Mohammed SI, Niccolai E, Nowsheen S, Vasantha Rupasinghe HP, Samadi A, Singh N, Talib WH, Venkateswaran V, Whelan RL, Yang X, Felsher DW. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol. 2015 Dec; 35 Suppl:S199-S223. PMID: 25865775.
      Citations: 102     Fields:    Translation:HumansCells
    27. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HMCS, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015 Dec; 35 Suppl:S185-S198. PMID: 25818339.
      Citations: 361     Fields:    Translation:HumansCells
    28. Amin ARMR, Karpowicz PA, Carey TE, Arbiser J, Nahta R, Chen ZG, Dong JT, Kucuk O, Khan GN, Huang GS, Mi S, Lee HY, Reichrath J, Honoki K, Georgakilas AG, Amedei A, Amin A, Helferich B, Boosani CS, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bhakta D, Halicka D, Niccolai E, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Bilsland A, Shin DM. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol. 2015 Dec; 35 Suppl:S55-S77. PMID: 25749195.
      Citations: 21     Fields:    Translation:HumansCells
    29. Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015 Dec; 35 Suppl:S224-S243. PMID: 25600295.
      Citations: 125     Fields:    Translation:Humans
    30. Azmi AS, Mohammad RM. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway? Future Med Chem. 2015; 7(1):5-7. PMID: 25582328.
      Citations:    Fields:    Translation:HumansCells
    31. Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS. Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition? Semin Cancer Biol. 2014 Aug; 27:39-45. PMID: 24954011.
      Citations: 33     Fields:    Translation:HumansAnimals
    32. Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget. 2014 Jun 15; 5(11):3444-54. PMID: 24899509.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    33. Bao B, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Aboukameel A, Mohammad R, Van Buren E, Azmi AS, Sarkar FH. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Stem Cells Dev. 2014 Aug 15; 23(16):1947-58. PMID: 24734907.
      Citations: 17     Fields:    Translation:HumansCells
    34. Bao B, Azmi AS, Ali S, Zaiem F, Sarkar FH. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med. 2014 Jun; 2(6):59. PMID: 25333034.
      Citations: 33     
    35. Azmi AS. The evolving role of nuclear transporters in cancer. Semin Cancer Biol. 2014 Aug; 27:1-2. PMID: 24793699.
      Citations: 6     Fields:    Translation:HumansAnimals
    36. Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem. 2014 May 23; 289(21):14520-33. PMID: 24719318.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    37. Azmi AS, Mohammad RM. Rectifying cancer drug discovery through network pharmacology. Future Med Chem. 2014 Apr; 6(5):529-39. PMID: 24649956.
      Citations: 7     Fields:    Translation:Humans
    38. Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther. 2014; 7:187-92. PMID: 24523592.
      Citations: 13     
    39. Choudhry ZS, Tripathi V, Sutton M, Bao B, Mohammad RM, Azmi AS. Regulation of KRAS-PAK4 axis by microRNAs in cancer. Curr Pharm Des. 2014; 20(33):5275-8. PMID: 24479809.
      Citations: 1     Fields:    Translation:HumansAnimals
    40. Bao B, Azmi AS, Li Y, Ahmad A, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther. 2014 Jan; 9(1):22-35. PMID: 23957937.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    41. Alian OM, Philip PA, Sarkar FH, Azmi AS. Systems biology approaches to pancreatic cancer detection, prevention and treatment. Curr Pharm Des. 2014; 20(1):73-80. PMID: 23530496.
      Citations: 5     Fields:    Translation:HumansAnimals
    42. Muqbil I, Kauffman M, Shacham S, Mohammad RM, Azmi AS. Understanding XPO1 target networks using systems biology and mathematical modeling. Curr Pharm Des. 2014; 20(1):56-65. PMID: 23530499.
      Citations: 7     Fields:    Translation:HumansCells
    43. Azmi AS. Systems and network biology in pharmaceutical drug discovery. Curr Pharm Des. 2014; 20(1):2-3. PMID: 23530505.
      Citations:    Fields:    
    44. Azmi AS, Bao B, Sarkar FH. Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev. 2013 Dec; 32(3-4):623-42. PMID: 23709120.
      Citations: 406     Fields:    Translation:HumansAnimalsCells
    45. Azmi AS. Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr Cancer Drug Targets. 2013 Nov; 13(9):906-14. PMID: 24168192.
      Citations: 12     Fields:    Translation:HumansCells
    46. Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014 Mar; 13(3):565-75. PMID: 24019208.
      Citations: 81     Fields:    Translation:HumansAnimalsCells
    47. Azmi AS, Bollig-Fischer A, Bao B, Park BJ, Lee SH, Yong-Song G, Dyson G, Reddy CK, Sarkar FH, Mohammad RM. Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. BMC Syst Biol. 2013 Sep 03; 7:85. PMID: 24004452.
      Citations: 11     Fields:    Translation:HumansCells
    48. Azmi AS, Mohammad RM. Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase". Haematologica. 2013 Sep; 98(9):e123. PMID: 24006415.
      Citations:    Fields:    Translation:HumansAnimals
    49. Muqbil I, Bao B, Abou-Samra AB, Mohammad RM, Azmi AS. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr Drug Targets. 2013 Sep; 14(10):1094-100. PMID: 23834155.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    50. Azmi AS, Sarkar FH, Hadi SM. Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property. F1000Res. 2013; 2:135. PMID: 24358870.
      Citations: 4     Fields:    
    51. Bao B, Ahmad A, Azmi AS, Ali S, Sarkar FH. Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol. 2013 Jun; Chapter 14:Unit 14.25. PMID: 23744710.
      Citations: 85     Fields:    Translation:HumansCells
    52. Azmi AS. Network pharmacology: an emerging field in cancer drug discovery). Curr Drug Discov Technol. 2013 Jun; 10(2):93-4. PMID: 23237671.
      Citations: 2     Fields:    
    53. Azmi AS. Adopting network pharmacology for cancer drug discovery. Curr Drug Discov Technol. 2013 Jun; 10(2):95-105. PMID: 23237672.
      Citations: 9     Fields:    Translation:HumansAnimals
    54. Azmi AS, Bao GW, Gao J, Mohammad RM, Sarkar FH. Network insights into the genes regulated by hepatocyte nuclear factor 4 in response to drug induced perturbations: a review. Curr Drug Discov Technol. 2013 Jun; 10(2):147-54. PMID: 23237677.
      Citations: 5     Fields:    Translation:HumansAnimals
    55. Wang Z, Ali S, Banerjee S, Bao B, Li Y, Azmi AS, Korc M, Sarkar FH. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. J Cell Physiol. 2013 Mar; 228(3):556-562. PMID: 22806240.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    56. Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica. 2013 Jul; 98(7):1098-106. PMID: 23403316.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    57. Muqbil I, Bao GW, El-Kharraj R, Shah M, Mohammad RM, Sarkar FH, Azmi AS. Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. J Stem Cell Res Ther. 2012 Dec 16; Suppl 7(5). PMID: 24319631.
      Citations: 5     
    58. Bao B, Ali S, Ahmad A, Azmi AS, Li Y, Banerjee S, Kong D, Sethi S, Aboukameel A, Padhye SB, Sarkar FH. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One. 2012; 7(12):e50165. PMID: 23272057.
      Citations: 59     Fields:    Translation:HumansCells
    59. Bao B, Li Y, Ahmad A, Azmi AS, Bao G, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSC-related miRNAs for cancer therapy by natural agents. Curr Drug Targets. 2012 Dec; 13(14):1858-68. PMID: 23140295.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    60. Alian OM, Azmi AS, Mohammad RM. Network insights on oxaliplatin anti-cancer mechanisms. Clin Transl Med. 2012 Oct 29; 1(1):26. PMID: 23369220.
      Citations: 8     
    61. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology. 2013 Feb; 144(2):447-456. PMID: 23089203.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    62. Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li Y, Banerjee S, Padhye S, Sarkar FH. Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One. 2012; 7(8):e43726. PMID: 22952749.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    63. Bao B, Ahmad A, Li Y, Azmi AS, Ali S, Banerjee S, Kong D, Sarkar FH. Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opin Ther Targets. 2012 Oct; 16(10):1041-54. PMID: 22877147.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    64. Azmi AS, Sarkar FH. Prostate cancer stem cells: molecular characterization for targeted therapy. Asian J Androl. 2012 Sep; 14(5):659-60. PMID: 22728671.
      Citations: 2     Fields:    
    65. Azmi AS, Mohammad RM, Sarkar FH. Can network pharmacology rescue neutraceutical cancer research? Drug Discov Today. 2012 Aug; 17(15-16):807-9. PMID: 22727577.
      Citations: 4     Fields:    
    66. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta. 2012 Dec; 1826(2):272-96. PMID: 22579961.
      Citations: 74     Fields:    Translation:HumansAnimalsCells
    67. Azmi AS. Network pharmacology for cancer drug discovery: are we there yet? Future Med Chem. 2012 May; 4(8):939-41. PMID: 22650234.
      Citations: 13     Fields:    Translation:HumansAnimals
    68. Shamim U, Hanif S, Albanyan A, Beck FW, Bao B, Wang Z, Banerjee S, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Resveratrol-induced apoptosis is enhanced in low pH environments associated with cancer. J Cell Physiol. 2012 Apr; 227(4):1493-500. PMID: 21678400.
      Citations: 17     Fields:    Translation:HumansCells
    69. Nishat S, Shabir H, Azmi AS, Ansari HR. A(3) adenosine receptor: a plausible therapeutic target for cardio-protection in diabetes. Recent Pat Cardiovasc Drug Discov. 2012 Apr; 7(1):59-70. PMID: 22300387.
      Citations: 5     Fields:    Translation:HumansAnimals
    70. Muqbil I, Beck FW, Bao B, Sarkar FH, Mohammad RM, Hadi SM, Azmi AS. Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol. Curr Pharm Des. 2012; 18(12):1645-54. PMID: 22288443.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    71. Azmi AS, Beck FW, Bao B, Mohammad RM, Sarkar FH. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics. 2011 Dec; 3(6):747-59. PMID: 22126293.
      Citations: 6     Fields:    Translation:HumansCells
    72. Bao B, Thakur A, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Ali S, Lum LG, Sarkar FH. The immunological contribution of NF-?B within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. Biochim Biophys Acta. 2012 Apr; 1825(2):160-72. PMID: 22155217.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    73. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012 Jan 01; 72(1):335-45. PMID: 22108826.
      Citations: 124     Fields:    Translation:HumansAnimalsCells
    74. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila). 2012 Mar; 5(3):355-64. PMID: 22086681.
      Citations: 152     Fields:    Translation:HumansAnimalsCells
    75. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem. 2011 Sep; 112(9):2296-306. PMID: 21503965.
      Citations: 102     Fields:    Translation:HumansCells
    76. Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Am J Transl Res. 2011 Aug 15; 3(4):374-82. PMID: 21904657.
      Citations: 5     
    77. Wang Z, Banerjee S, Ahmad A, Li Y, Azmi AS, Gunn JR, Kong D, Bao B, Ali S, Gao J, Mohammad RM, Miele L, Korc M, Sarkar FH. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-?B signaling pathways. PLoS One. 2011; 6(6):e20537. PMID: 21673986.
      Citations: 28     Fields:    Translation:AnimalsCells
    78. Masood A, Azmi AS, Mohammad RM. Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. Cancers (Basel). 2011 Jun 01; 3(2):1527-49. PMID: 21760983.
      Citations: 14     
    79. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011 May; 2(5):378-92. PMID: 21623005.
      Citations: 28     Fields:    Translation:HumansCells
    80. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011 Aug 01; 307(1):26-36. PMID: 21463919.
      Citations: 152     Fields:    Translation:HumansCells
    81. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 2011 Apr; 31(4):1105-13. PMID: 21508353.
      Citations: 34     Fields:    Translation:HumansCells
    82. Muqbil I, Masood A, Sarkar FH, Mohammad RM, Azmi AS. Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. Cancers (Basel). 2011 Jan 21; 3(1):428-45. PMID: 24212623.
      Citations: 8     
    83. Azmi AS. Pharmaceutical reactivation of p53 pathways in cancer. Curr Pharm Des. 2011; 17(6):534-5. PMID: 21391903.
      Citations: 3     Fields:    Translation:HumansAnimals
    84. Azmi AS, Beck FW, Sarkar FH, Mohammad RM. Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr Pharm Des. 2011; 17(6):640-52. PMID: 21391913.
      Citations: 5     Fields:    Translation:Humans
    85. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Wojewoda C, Miele L, Sarkar FH. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2011 Jan; 112(1):78-88. PMID: 20658545.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    86. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, Sarkar FH. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 2011 Jan; 8(1):27-33. PMID: 21102532.
      Citations: 148     Fields:    Translation:HumansCells
    87. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S, Sarkar FH. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer. 2011 03 01; 128(5):1240-50. PMID: 20824697.
      Citations: 8     Fields:    Translation:AnimalsCells
    88. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther. 2010 Dec; 9(12):3137-44. PMID: 21041384.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    89. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2011 Mar; 16(1):59-70. PMID: 20812891.
      Citations: 35     Fields:    Translation:Humans
    90. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat. 2010 Aug-Oct; 13(4-5):109-18. PMID: 20692200.
      Citations: 135     Fields:    Translation:HumansCells
    91. Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Sarkar FH. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010 Dec; 1806(2):258-67. PMID: 20600632.
      Citations: 93     Fields:    Translation:HumansCells
    92. Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets. 2010 Jun; 14(6):611-20. PMID: 20426700.
      Citations: 9     Fields:    Translation:HumansAnimals
    93. Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 Jun; 10(6):518-26. PMID: 20377522.
      Citations: 1     Fields:    Translation:Humans
    94. Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010 May; 10(3):319-31. PMID: 20370686.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    95. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, Sarkar FH. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta. 2010 Aug; 1806(1):122-30. PMID: 20434526.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    96. Banerjee S, Azmi AS, Padhye S, Singh MW, Baruah JB, Philip PA, Sarkar FH, Mohammad RM. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res. 2010 Jun; 27(6):1146-58. PMID: 20422266.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    97. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer. 2010 Apr; 46(6):1122-31. PMID: 20156675.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    98. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009 Dec 03; 8:115. PMID: 19958544.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    99. Ullah MF, Shamim U, Hanif S, Azmi AS, Hadi SM. Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Mol Nutr Food Res. 2009 Nov; 53(11):1376-85. PMID: 19743405.
      Citations: 13     Fields:    Translation:HumansCells
    100. Nazeem S, Azmi AS, Hanif S, Ahmad A, Mohammad RM, Hadi SM, Kumar KS. Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis. 2009 Sep; 24(5):413-8. PMID: 19505895.
      Citations: 11     Fields:    Translation:HumansCells
    101. Azmi AS, Mohammad RM. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol. 2009 Jan; 218(1):13-21. PMID: 18767026.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    102. Shamim U, Hanif S, Ullah MF, Azmi AS, Bhat SH, Hadi SM. Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: implications for an anticancer mechanism. Free Radic Res. 2008 Aug; 42(8):764-72. PMID: 18661438.
      Citations: 12     Fields:    Translation:HumansCells
    103. Hanif S, Shamim U, Ullah MF, Azmi AS, Bhat SH, Hadi SM. The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. Toxicology. 2008 Jul 10; 249(1):19-25. PMID: 18486296.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    104. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008 Apr; 34(2):122-36. PMID: 18162327.
      Citations: 158     Fields:    Translation:Humans
    105. Hadi SM, Bhat SH, Azmi AS, Hanif S, Shamim U, Ullah MF. Oxidative breakage of cellular DNA by plant polyphenols: a putative mechanism for anticancer properties. Semin Cancer Biol. 2007 Oct; 17(5):370-6. PMID: 17572102.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    106. Muqbil I, Azmi AS, Banu N. Prior exposure to restraint stress enhances 7,12-dimethylbenz(a)anthracene (DMBA) induced DNA damage in rats. FEBS Lett. 2006 Jul 10; 580(16):3995-9. PMID: 16806193.
      Citations: 11     Fields:    Translation:AnimalsCells